Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function
British Journal of Pharmacology · 2024-01 · 181 (2) · 257-272
DOI: 10.1111/bph.16054 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Pharmacology, 2023-03. Verfasst von Wei Zou und 11 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, …. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Natural Science Foundation of China, Graduate Research and Innovation Projects of Jiangsu Province.
Abstract (Originalsprache)
Programmed cell death protein‐1 (PD‐1)/programmed death ligand‐1 (PD‐L1) immune checkpoint blockade as a breakthrough in cancer immunotherapy has shown unprecedented positive outcomes in the clinic. However, the overall effectiveness of PD‐L1 antibody is less than expected. An increasing number of studies have demonstrated that PD‐L1 is widely distributed and expressed not only on the cell membrane but also on the inside of the cells as well as on the extracellular vesicles secreted by tumour cells. Both endogenous and exogenous PD‐L1 play significant roles in influencing the therapeutic effect of anti‐tumour immunity. Herein, we mainly focused on the distribution and function of PD‐L1 and further summarized the potential targeted therapeutic strategies. More importantly, in addition to taking the overall expression abundance of PD‐L1 as a predictive indicator for selecting corresponding PD‐1/PD‐L1 monoclonal antibodies (mAbs), we also proposed that personalized combination therapies based on the different distribution of PD‐L1 are worth attention to achieve more efficient and effective therapeutic outcomes in cancer patients. LINKED ARTICLES This article is part of a themed issue on Cancer Microenvironment and Pharmacological Interventions. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v181.2/issuetoc
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, China.
- Department of Biochemistry and Molecular Biology, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- Jiangsu Joint International Research Laboratory of Chinese Medicine and Regenerative Medicine, Nanjing University of Chinese Medicine, Nanjing, China.
- Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, China.
- Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, California, USA.
ORCID-Profile: Zhonghong Wei
Förderung
- NCI NIH HHS
- National Natural Science Foundation of China
- Graduate Research and Innovation Projects of Jiangsu Province
Zitieren
APA
Zou, W., Luo, X., Gao, M., Yu, C., Wan, X., Yu, S., Wu, Y., Wang, A., Fenical, W., Wei, Z., Zhao, Y., & Lu, Y. (2024). Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function. British Journal of Pharmacology, 181(2), 257-272. https://doi.org/10.1111/bph.16054
Vancouver
Zou W, Luo X, Gao M, Yu C, Wan X, Yu S, et al. Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function. British Journal of Pharmacology. 2024;181(2):257-272. doi:10.1111/bph.16054
BibTeX
@article{Zou2024,
author = {Zou, Wei and Luo, Xin and Gao, Mengyuan and Yu, Chang and Wan, Xueting and Yu, Suyun and Wu, Yuanyuan and Wang, Aiyun and Fenical, William and Wei, Zhonghong and Zhao, Yang and Lu, Yin},
title = {Optimization of cancer immunotherapy on the basis of programmed death ligand‐1 distribution and function},
journal = {British Journal of Pharmacology},
year = {2024},
volume = {181},
number = {2},
pages = {257--272},
doi = {10.1111/bph.16054}
}
EUVIMED